1. Introduction

 Diagnostic and therapeutic angiographic procedures are increasingly performed. Many complex interventions are lengthy and require large dosages of contrast medium (CM). Radiological procedures such as coronary angiography require intravascular administration of iodinated CM is becoming a great source of an iatrogenic disease known as contrast-induced nephropathy (CIN). The pathogenesis of CIN is unclear. The proposed mechanisms are outer-medullary hypoxia due to decreased renal blood flow secondary to renal artery vasoconstriction. Tubular obstruction, apoptosis and oxidative damage, endothelial dysfunction, defective prostaglandin synthesis, and autonomic dysfunction are other proposed mechanisms.

 Patients who develop CIN have higher complication rates, longer hospital stays, and higher mortality than patients who do not develop CIN. Nearly one-third of the patients who require in-hospital dialysis because of CIN die prior to discharge. No current treatment can reverse or ameliorate CIN once it occurs. The occurrence of CIN is directly related to the number of pre-existing patient risk markers. After the high-risk patient population has been identified and risk markers addressed, the next step in preventing CIN is the use of different prophylactic therapies. The strongly associated risk markers for CIN are pre-existing renal failure, diabetes mellitus, age greater than 70 years, concurrent use of nephrotoxic drugs, hypovolemia, use of a large amount of CM or an ionic hyperosmolar CM, and congestive heart failure.

 Aim of the present chapter is to summarize the knowledge about the risk factors and prophylactic treatments of CIN according to the ultimate clinical research and developments.
2. Definition of CIN

A universally accepted definition of CIN does not exist. The most commonly used definition for CIN is the elevation of serum creatinine by ≥0.5mg/dl or ≥25% occurring within 48 hours after administration of CM, and the absence of an alternative etiology. Using the Cockcroft-Gault and the Modification of Diet in Renal Disease equations are useful in estimation of the GFR. Serum cystatin C has been proposed as an alternative endogenous marker of GFR showing higher correlation to standard clearance methods such as inulin or iohexol clearance. Serum cystatin C may detect CIN one to two days earlier than creatinine. Recent studies documented that serum and urine neutrophil gelatinase-associated lipocalin is an early predictive biomarker of CIN (Shaker et al., 2010). Urinary interleukin 18 and urinary liver-type fatty acid-binding protein are new potential biomarkers of CIN (Perrin et al., 2012). Cholesterol atheroemboli, volume depletion, and interstitial nephritis should consider in differential diagnosis of CIN. The incidence of CIN is reported to be 0.6-2.3% in general population who do not have any risk factor for CIN, but the incidence can be increased to 90% in patients at high risk for CIN (Toprak, 2007).

2.1. Pathophysiology of CIN

The potential pathophysiologic mechanisms of CIN were summarized in Figure 1. Medullary hypoxia due to decreased renal blood flow secondary to renal artery vasoconstriction, tubular obstruction, direct tubular toxicity of the CM due to apoptosis, oxidative damage, endothelial dysfunction, and renal microcirculatory alterations may play a role in the pathogenesis of CIN.

2.2. Clinical course and outcomes

CIN may range in severity from asymptomatic, nonoliguric transient renal dysfunction to oliguric severe renal failure that necessitates permanent dialysis. CIN is reported to be the third leading cause of in-hospital acute renal failure after hypotension and surgery. Approximately $180 million is spent annually to manage CIN in the US. Dangas et al. showed that in-hospital outcomes such as death (6.3% vs 0.8%), cardiac death (4.0% vs 0.5%), coronary artery bypass grafting (5.8% vs 0.5%), major adverse cardiac event (9.3% vs 1.1%), packed red cell transfusion (28% vs 6%), vascular surgery of access site (5.6% vs 2.6%), post-procedure length of stay (6.8±7.1 vs 2.3±2.5) were significantly higher in CIN developed patients compare with control (p<0.0001). In cumulative one-year outcome death, out-of-hospital death and major adverse cardiac events were significantly higher in CIN developed patients (p<0.0001) (Dangas et al., 2005). In a study of acute myocardial infarction patients undergoing primary angioplasty, it was found that CIN developed patients have significantly higher incidence of high-rate atrial fibrillation (p=0.01), high-degree conduction disturbances requiring permanent pacemaker (p=0.04), acute pulmonary edema (p=0.008), respiratory failure requiring mechanical ventilation (p<0.0001), cardiogenic shock requiring intra-aortic balloon (p<0.0001), and acute renal failure requiring renal replacement therapy (p<0.0001) (Marenzi et al., 2004).
2.3. Risk Factors for CIN

Specific factors that increase the risks for development of CIN are related to the patient, the contrast media, and the procedure (Table 1).

| Risk Factors                          | Odds Ratio (95%CI) | p Value |
|---------------------------------------|--------------------|---------|
| Kidney Related Risk Factors           |                    |         |
| Pre-existing renal failure            |                    |         |
| Preprocedural creatinine 2.0-2.9 mg/dl| 7.37 (4.78-11.39)  | <0.0001 |
| Preprocedural creatinine ≥ 3mg/d       | 12.82 (8.01-20.54) | <0.0001 |
| Diabetes mellitus-Diabetic nephropathy|                    |         |
| Risk Factors                                                                 | Odds Ratio (95%CI)   | p Value     |
|-----------------------------------------------------------------------------|---------------------|-------------|
| Preprocedural creatinine ≤ 1.1mg/dl                                        | 1.86 (1.20-2.89)    | 0.005       |
| Preprocedural creatinine 1.2-1.9 mg/dl                                     | 2.42 (1.54-3.79)    | <0.001      |
| Use of nephrotoxic drugs                                                   |                     |             |
| Low effective circulatory volume                                           | 1.19 (0.72-1.95)    | 0.05        |
| **Cardiovascular System Related Risk Factors**                             |                     |             |
| Class III-IV congestive heart failure                                       | 2.20 (1.60-2.90)    | <0.0001     |
| Left ventricle ejection fraction ≤40%                                       | 1.57 (1.14-2.16)    | 0.005       |
| Acute myocardial infarction ≤ 24 h                                         | 1.85 (1.31-2.63)    | 0.0006      |
| Hypertension                                                               | 2.00 (1.40-2.80)    | 0.0001      |
| Periprocedural hypotension                                                 | 2.50 (1.70-3.69)    | <0.00001    |
| Multi-vessel coronary involvement                                          | 3.24 (1.07-9.82)    | 0.038       |
| Peripheral vascular disease                                                | 1.90 (1.40-2.70)    | <0.0001     |
| Preprocedure shock                                                         | 1.19 (0.72-1.96)    | 0.05        |
| Using intra-aortic balloon pump                                            | 15.51 (4.65-51.64)  | <0.0001     |
| Bypass graft intervention                                                  | 4.94 (1.16-20.9)    | 0.03        |
| Time-to-reperfusion ≥6 h                                                   | 2.51 (1.01-6.16)    | 0.04        |
| Pulmonary edema                                                            | 2.56 (1.42-4.52)    | 0.001       |
| **Demographic Risk Factors**                                               |                     |             |
| Age >75 years                                                               | 5.28 (1.98-14.05)   | 0.0009      |
| Female gender                                                              | 1.4 (1.25-1.60)     | 0.0001      |
| Contrast Media Related Risk Factors                                        |                     |             |
| High total dose of contrast agent ("/>300 ml)                             | 2.8 (1.17-6.68)     | 0.02        |
| Osmolality (Low- vs. high-osmolality)                                      | 0.50 (0.36-0.68)    | 0.03        |
| Short duration of two contrast administration                              | 4.4 (2.9-6.5)       | <0.0001     |
| **Other Possible Risk Factors**                                            |                     |             |
| Procedural success                                                         | 0.27 (0.19-0.38)    | <0.0001     |
| Baseline hematocrit                                                        | 0.95 (0.92-0.97)    | <0.00001    |
| Hyperuricemia                                                              | 4.71 (1.29-17.21)   | 0.019       |
| ACE inhibitors                                                             | 3.37 (1.14-9.94)    | 0.028       |
| Angiotensin Receptor Blockers                                             | 2.70 (1.25-5.81)    | 0.011       |
| Metabolic Syndrome                                                        | 426 (1.19-15.25)    | 0.026       |
| Hypoalbuminemia                                                            | 5.79 (1.71-19.64)   | 0.005       |
| Hypercholesterolemia                                                       |                     |             |
| Renal transplant                                                           |                     |             |
| Multiple myeloma                                                           |                     |             |
| Diuretics                                                                  |                     |             |
| Intra-arterial contrast administration                                     |                     |             |
| Sepsis, cirrhosis                                                          |                     |             |

*Table 1.* Risk factors for the development of contrast-induced nephropathy
2.3.1. Patient-related risk factors

2.3.1.1. Pre-existing renal disease

The major risk factor for CIN is a GFR<60 ml/min/1.73 m². Chronic kidney disease is associated with decreased vasodilatory response, which is important in developing CIN, and in patients with renal insufficiency, the clearance of CM is slower than in normal subjects. In a study of 7586 patients who underwent coronary intervention, CIN developed in 22.4% of the patients who had serum creatinine levels of 2.0 to 2.9 mg/dl and in 30.6% of those with serum creatinine levels of 3.0 mg/dl or higher, compared with 2.4% of patients with serum creatinine levels <1.1 mg/dl (Rihal et al., 2002). Two other studies (Moore et al., 1992; Barrett et al., 1992) reported that the incidence of CIN increased from 4% to 20% as the baseline serum creatinine increased from 1.2 to 2.9 mg/dl. In another study, the incidence of CIN increased from 8% to 92% as the serum creatinine increased from 1.5 to 6.8 mg/dl. Furthermore, the probability of CIN requiring dialysis increases from 0.04% to 48% as the baseline GFR decreases from 50 to 10 ml/min (McCullough et al., 1997).

2.3.1.2. Diabetes mellitus

Nitric oxide-dependent renal vasodilatation is characteristically altered and renal outer medullary pO₂ is significantly reduced in diabetes mellitus. Chronic kidney disease and DM are associated with endothelial dysfunction and decreased vasodilatory responses. Diabetic nephropathy has been identified as a powerful and independent risk factor for CIN. Patients with diabetic nephropathy and a mean serum creatinine of 6.8 mg/dl had a 92% incidence of CIN after coronary angiography (Weinrauch et al., 1977). Patients with diabetes who have advanced chronic renal failure because of causes other than diabetic nephropathy are at significantly higher risk of developing CIN like diabetic nephropathy. On the other hand, studies have shown that when pre-existing renal disease is present, patients with and without diabetes are similarly at risk of CIN, which correlates with the degree of renal disease. Some authors have suggested that DM in the absence of nephropathy, particularly in insulin-dependent patients with diabetes, is associated with an increased risk of CIN (McCullough et al., 1997; Toprak 2007). In a study, it was found that the incidence of CIN was rather low (2%) in patients with neither diabetes nor azotemia, significantly higher (16%) in individuals with diabetes but preserved renal function, and much higher (38%) in patients who had both diabetes and azotemia (Lautin et al., 1991). In another study, the incidence of CIN was found to be 2% in patients without diabetes and 3.7% in patients with diabetes with a baseline creatinine of 1.1 mg/dl or less (OR=1.86, p=0.005). When renal function is mildly impaired (serum creatinine level 1.2 to 1.9 mg/dl), the risk of CIN in patients with diabetes mellitus increases to 4.5% (OR=2.42, p=0.001) (Rihal et al., 2002). Other studies have failed to corroborate this connection (Parfrey et al., 1989). However, given that, those with diabetes alone were found to be at slightly higher risk of CIN than the general population.
2.3.1.3. Pre-diabetes

In a study of 421 patients who underwent coronary angiography with renal insufficiency, we presented that pre-DM increase the incidence of CIN 2.1-fold in comparison to patients with normal fasting glucose (NFG) but pre-DM is not as strong as DM as a risk of developing CIN. CIN occurred in 20% of the DM (RR=3.6, p=0.001), 11.4% of the pre-DM (RR 2.1, p=0.314) and 5.5% of the NFG group. The decrease of GFR was higher in DM and pre-DM (p=0.001 and p=0.002, respectively). Length of hospital stay was 2.45 ± 1.45 day in DM, 2.27 ± 0.68 day in pre-DM, and 1.97 ± 0.45 day in NFG (p<0.001, DM vs. NFG and p=0.032, pre-DM vs. NFG). The rate of major adverse cardiac events was 8.7% in DM, 5% in pre-DM, and 2.1% in NFG (p=0.042, DM vs. NFG). Hemodialysis was required in 3.6% of DM, and 0.7% in pre-DM (p=0.036, DM vs. NFG), and the total number of hemodialysis sessions during 3 months was higher in DM and pre-DM (p<0.001). Serum glucose ≥124 mg/dl was the best cut-off point for prediction of CIN (Toprak et al., 2007).

2.3.1.4. Metabolic syndrome, impaired fasting glucose and hypertriglyceridemia

In a prospective cohort study of 219 non-diabetic elderly patients with reduced kidney function who underwent elective coronary angiography, we reported that metabolic syndrome was a risk indicator of CIN (OR=4.26, p=0.026). CIN occurred in 14% of the metabolic syndrome group and 3.6% of the non-metabolic syndrome group (relative risk 3.93, p=0.007). Impaired fasting glucose (OR=4.72, p=0.007), high triglyceride (OR=4.06, p=0.022); and multivessel involvement (OR=3.24, p=0.038) in the metabolic syndrome group were predictors of CIN (Toprak et al., 2006).

2.3.1.5. Hyperuricemia

Contrast agents have a uricosuric effect, which appears to be caused by enhanced renal tubular secretion of uric acid. Furthermore, hyperuricemia is accompanied by enhanced synthesis of reactive oxygen species, tubular obstruction by uric acid, an activated renin–angiotensin–aldosterone system, increased endothelin-1, and an inhibited nitric oxide system which plays a role in the pathogenesis of CIN. In a prospective cohort study we evaluated 266 patients who undergoing elective coronary angiography and we found that patients with hyperuricemia are at risk of developing CIN (OR=4.71, p=0.019). CIN occurred in 15.1% of the hyperuricemic group and 2.9% of the normouricemic group (p<0.001). Length of hospital stay (p<0.001) and CIN requiring renal replacement therapy (p=0.017) were significantly higher in hyperuricemic group. Serum uric acid ≥7 mg/dl in males and ≥5.9 mg/dl in females were found the best cut-off value for prediction of CIN (Toprak et al., 2006).

2.3.1.6. Hypercholesterolemia

Altered nitric oxide-dependent renal vasodilatation is prevalent in hypercholesterolemia. Hypercholesterolemia aggravates CIN through the reduced production of nitric oxide (Yang et al., 2004).
2.3.1.7. Multivessel Coronary involvement, peripheral vascular disease, and renal artery stenosis

If a patient has multivessel coronary involvement, the other vessels in the body, such as the renal artery, can be involved. If the renal artery is involved, the renal blood supply may decrease and the kidneys may be more susceptible to CIN. Factors related to accelerated or diffuse atherosclerosis are linked to the development of CIN. The treatment of multivessel disease, challenging chronic total occlusions and extensively diseased coronary segments, may require high doses of CM for providing an optimal image quality, thus enhancing the potential toxic effects on the renal function. In a study of 177 patients who underwent cardiac catheterization, subjects were also evaluated for renal artery stenosis. Coronary artery disease was detected in 110 patients (62%), and significant renal artery stenosis was detected in 19 patients (11%). Using multivariate analysis, it was found that the extent of coronary artery disease was an independent predictor of renal artery stenosis (Weber-Mzell et al., 2002). In a study a total of 5571 patients who underwent PCI were evaluated for CIN risk factors, and it was found that multivessel coronary involvement was only a univariate predictor of CIN (p=0.003) (Mehran et al., 2004). In two other cohort studies it was found that peripheral vascular disease is a risk for CIN in patients who underwent PCI (OR=1.9, p<0.0001 and OR=1.71, p=0.001, respectively) (Bartholomew et al., 2004; Rihal et al., 2002). In a study a total of 219 non-diabetic patients who underwent coronary angiography we have found that multivessel coronary involvement is a risk for CIN (OR=3.24, p=0.038) (Toprak et al., 2006).

2.3.1.8. Older age

In a prospective study in which elderly patients (≥70 years) were subjected to cardiac catheterization, 11% developed CIN (Rich & Crecelius, 1990). In another study, CIN incidence was 17% in elderly patients (>60 years) as compared with 4% in younger patients (Kohli et al., 2000). In 208 patients with acute myocardial infarction who underwent coronary intervention, it was found that an age of ≥75 years was an independent risk for CIN (OR=5.28, p=0.0009) (Marenzi et al., 2004). The possible reasons of the high incidence of CIN in elderly were age-related changes in renal function, more difficult vascular access following tortuosity, calcification of the vessels requiring greater amount of CM, defective prostaglandin synthesis, and the presence of renovascular disease. Furthermore, hypovolemia is very common in elderly patients.

2.3.1.9. Gender

Ovarian hormones can affect the renin–angiotensin system and renal blood flow. In a retrospective study of 8628 patients who underwent PCI, female sex was an independent predictor of CIN (OR=1.4, p<0.0001). One-year outcome analyses by gender showed a higher mortality among females than among males in a cohort of CIN patients (14% vs 10%, p=0.05) (Iakovou et al., 2003). The findings of this study contradict those of a previous randomized controlled trial of ionic vs nonionic CM, in which a multivariate analysis identified male gender as an independent risk factor for CIN (Rudnick et al., 1995).
2.3.1.10. Hypovolemia

Hypovolemia leads to active sodium reabsorption, which is an oxygen-demanding process, and increases neurohumoral vasoconstrictive stimuli that might compromise medullary oxygenation. The toxic effects of CM on the renal tubular lumen may be exacerbated in hypovolemia. Decreased effective circulating volume and reduced renal perfusion potentiate renal vasoconstriction after administration of intravascular CM. Volume expansion reduces the activity of the renin–angiotensin system, minimizes increases in blood viscosity and osmolality, and increases medullary perfusion. At present the most convincing preventive procedure of CIN is adequate hydration with isotonic saline or sodium bicarbonate. Before coronary angiography, the volume status of patients can be assessed through the inferior vena cava index, mean atrial pressure, noninvasive pulmonary-capillary wedge pressure or bioimpedance spectroscopy (Toprak & Cirit, 2005).

2.3.1.11. Congestive heart failure and reduced left ventricular ejection fraction

Advanced heart failure and reduced LVEF are characterized by effective volume depletion caused by low cardiac output and increased neurohumoral vasoconstrictive stimuli and impaired nitric oxide-dependent renal vasodilatation that might compromise medullary oxygenation. Studies have shown that reduced left ventricular ejection fraction (LVEF) (≤49%) and advanced congestive heart failure (New York Heart Association class III or IV) are independent risk factors for CIN. In a study, Dangas et al. showed that LVEF below 40% is an independent predictor of CIN (Dangas et al., 2005). We have previously reported that if the LVEF is greater than 30%, this condition does not show any significant effect on the development of CIN (Toprak et al., 2003). In a study it was shown that congestive heart failure was an independent risk for CIN (OR=1.53, p=0.007) (Rihal et al., 2002). In a cohort study it was found that congestive heart failure is a risk for CIN in patients who underwent PCI (OR=2.2, p<0.0001) (Bartholomew et al., 2004).

2.3.1.12. Hypertension

An explanation for hypertension as a risk factor for CIN is: alterations in the intrarenal expression of vasoactive mediators, such as the renin-angiotensin system or nitric oxide, may be contributing factors. Impaired nitric oxide-dependent renal vasodilatation is prevalent in individuals who are hypertensive. Finally, a reduced number of nephrons could predispose hypertensive patients to CIN. In a study of 8628 patients who underwent percutaneous interventions, hypertension was found to be an independent predictor of CIN (OR=1.2, p=0.0035). In a cohort study Bartholomew et al. found that hypertension is a risk for CIN in patients who underwent PCI (OR=2.0, p=0.0001) (Bartholomew et al., 2004).

2.3.1.13. Nephrotoxic drugs

Directly, nephrotoxic drugs and those that inhibit the vasodilatory effects of prostaglandins have been reported to render the kidney more vulnerable to CM. Sulfonamides, aminoglycosides, and their combinations with furosemide are particularly potent. Cyclosporin A may
intensify medullary hypoxia, and cisplatin can attach to sulfhydryl groups. Mannitol can increase the metabolic workload in the kidney, and amphotericin B can cause the effect of a combination of mannitol and cyclosporine A. Nonselective NSAIDs and selective COX-2 inhibitors decrease the vasodilatory prostaglandins in the kidney and potentiate the vasoconstrictive effect of CM.

2.3.1.14. Metformin

Patients who are receiving metformin may develop lactic acidosis as a result of CIN. A decline in renal function after contrast exposure could adversely affect the clearance of metformin. The complication was almost always observed in diabetic patients with decreased renal function before injection of CM. A meta-analysis by the Cochrane Library with pooled data from 176 comparative trials and cohort studies revealed no cases of fatal or nonfatal lactic acidosis in 35,619 patient-years of metformin use or in 30,002 patients-years in the non-metformin group. It seems safer to instruct patients especially at high risk for CIN not to take this drug for 48 h or so after CM administration and resume taking the drug only if there are no signs of nephrotoxicity.

2.3.1.15. ACE inhibitors and angiotensin receptor blockers

ACE inhibitors have been identified as a risk factor for CIN because of their potential to reduce renal function. On the other hand, some small studies have shown that the nephrotoxicity of CM may be reduced because of decreased renal vasoconstriction by inhibition of angiotensin II. Renal vasoconstriction occurs after the CM administration and the renin–angiotensin system is responsible for this vasoconstriction. In a randomized controlled study with 71 patients with diabetes who underwent coronary angiography randomized to captopril or control, 25-mg captopril was given three times daily. There was a significant decrease in CIN in the patients who received captopril compared with the control group (6% vs 29%, respectively, p<0.02) (Gupta et al., 1999). We have performed a randomized controlled study in 80 patients with serum creatinine below 2 mg/dl who underwent coronary angiography. Captopril was administered in 48 patients before coronary angiography. Five patients (10.4%) in the captopril group developed CIN, compared with only one patient (3.1%) in the control group (p=0.02) (Toprak et al., 2003). In a study of 230 patients with renal insufficiency and age ≥65 years we found that chronic ACE inhibitor administration was a risk for developing CIN. CIN occurred in 17 patients (15.6%) in the ACE inhibitor group and 7 patients (5.8%) in the control group (p=0.015). Serum creatinine level increased from 1.34 ± 0.20 to 1.53 ± 0.27 mg/dl in the ACE inhibitor group and from 1.33 ± 0.18 to 1.45 ± 0.19 mg/dl in the control group (p<0.001). Chronic ACE inhibitor administration was a risk indicator of CIN (OR=3.37, p=0.028) (Cirit et al., 2006). In another study, 421 patients with renal insufficiency who underwent coronary angiography, use of ACE inhibitors or ARB was a risk for CIN in multivariate analysis (OR=2.7, p=0.011) (Toprak et al., 2007). In a recent study, the impact of renin-angiotensin and aldosterone system blockade on the frequency of CIN was assessed retrospectively. Patients treated with ACE inhibitors or ARB (n=269) and were not treated with them (n=143) underwent coronary angiography included to the study. CIN developed
11.9% in ACE-inhibitor using group and 4.2% in control group (p=0.006). Use of ARB or ACE inhibitors was found as a risk for CIN (OR=3.08, p=0.016) (Kiski et al., 2010). Checking the use of ACE inhibitors or ARB before coronary angiography seems to be a useful guide in tracking risk assessment for CIN. It is reasonable to suggest that there is a need to hold ACE inhibitor or ARB use before coronary angiography.

2.3.1.16. Multiple myeloma

Multiple myeloma has been suggested as a potential risk factor for CIN. The pathomechanism of this process has been explained by the precipitation of CM molecules together with Tamm–Horsfall proteins and other abnormal proteins, tubular epithelial cells damaged and desquamated as a result of ischemia, direct contrast toxicity, or disturbed function of integrins. Intratubular light chains, particularly in the setting of intravascular volume depletion, have been found to augment the nephrotoxic potential of CM (Holland et al., 1985). Studies with a broader scope have since shown that the observed risk is linked to coexisting risk factors, such as pre-existing renal insufficiency, low circulating volume, proteinuria, amyloidosis, hyperuricemia, and hypercalcemia rather than to myeloma itself. Studies showed an incidence of CIN of only 0.6–1.25% in patients with myeloma if dehydration is avoided (McCarthy & Becker, 1992).

2.3.1.17. Renal transplantation

Patients with renal transplantation may be at a higher risk of CIN due to concomitant use of cyclosporine and higher prevalence of diabetes and renal insufficiency. In a study, 33 patients with a functioning renal allograft who underwent different contrast studies, the incidence of CIN was 21.2% (Ahuja et al., 2000).

2.3.1.18. Acute myocardial infarction

A study by Rihal et al. showed that acute myocardial infarction within 24 h before administration of the CM is a risk factor for CIN (OR=1.85, p=0.0006). This study demonstrates that CIN is a frequent complication in acute myocardial infarction, even in patients with a normal baseline renal function. (Rihal et al., 2002). In a study of 208 acute myocardial infarction patients who underwent primary PCI, anterior acute myocardial infarction was significantly higher in patients who developed CIN (p=0.0015). However, in multivariate analysis, anterior acute myocardial infarction (OR=2.17, p=0.09) was not a risk for CIN (Marenzi et al., 2004). In 2082 percutaneous interventions for acute myocardial infarction, it was reported a more than seven-fold (3.2% vs 23.3%) increase in 1-year mortality in patients who developed CIN (Sadeghi et al., 2003).

2.3.1.19. Anemia

Anemia-induced deterioration of renal ischemia may be one plausible explanation for the higher incidence of CIN in patients with a low hematocrit level. A baseline hematocrit value of less than 39% for men and less than 36% for women is a risk for CIN. The relationship
between low hematocrit levels and CIN has been investigated in a prospective study of 6773 patients who underwent PCI (Nikolsky et al., 2005). A lower baseline hematocrit was an independent predictor of CIN; and each 3% decrease in baseline hematocrit resulted in a significant increase in the odds of CIN in patients with and without chronic kidney disease (11% and 23%, respectively). Dangas et al. showed that the baseline hematocrit level is an independent predictor of CIN in patients with chronic kidney disease (OR=0.95, p<0.00001) (Dangas et al., 2005).

2.3.1.20. Low serum albumin

Hypoalbuminemia impairs endothelial function, enhances renal vasoconstriction, impairs the synthesis and release of nitric oxide, and decreases antioxidant enzyme activity. In a study, low serum albumin (<3.5 g/dl) was identified as a risk factor for CIN in patients 70 years of age or older who underwent cardiac catheterization (Rich, et al., 1990). Also we have found that in 230 patients who underwent coronary angiography with renal insufficiency, serum albumin level ≤3.5 g/dl was a risk factor for CIN (OR=5.79, p=0.005) (Cirit et al., 2006).

2.3.1.21. Hypotension, sepsis, cirrhosis, and pulmonary edema

A systolic blood pressure of less than 80 mm Hg for at least 1 h that requires inotropic support with medications is a risk factor for CIN. A study by Dangas et al showed that periprocedural hypotension and pulmonary edema are independent predictors of CIN in patients with chronic kidney disease (OR=2.50, p<0.00001 and OR=2.56, p=0.001, respectively) (Dangas et al., 2005) Sepsis, through direct damage by bacterial toxins to renal tubules and impairment of circulation, has also been reported as a risk factor. Reduction of effective intravascular volume caused by liver cirrhosis has been reported as contributing to pre-renal reduction in renal perfusion, thus enhancing the ischemic insult of CM (Toprak, 2007).

2.3.2. Procedure-related risk factors

2.3.2.1. Short duration of the two contrast administration and urgent/emergency procedure

In those who have no risk factors for CIN, angiography should be delayed more than 48 hours after a previous exposure to intravascular contrast media. In patients with diabetes or preexisting renal disease, this time interval should be increased to more than 72 hours. In a cohort study, urgent/emergency procedure was found as a predictor of CIN (OR=4, p<0.00001) (Bartholomew et al., 2004). The higher risk of developing CIN in patients with urgent status was irrespective of baseline renal function.

2.3.2.2. Use of intra-aortic balloon pump

Using intra-aortic balloon pump may signify a very high-risk population due to very severe coronary atherosclerosis and/or indicate a role of atheroembolism. In 208 consecu-
tive acute myocardial infarction patients undergoing percutaneous coronary intervention, use of intra-aortic balloon pump was a risk predictor of CIN (OR=15.51, p<0.0001) (Marenzi et al., 2004). In a study, it has demonstrated that, intra-aortic balloon pump use is an independent predictor of CIN in patients with chronic kidney disease (OR=2.27, p=0.004) (Dangas et al., 2005). In another study, it was found that the use of intra-aortic balloon pump was a risk factor for CIN requiring dialysis after PCI (OR=1.94) (Gruberg et al., 2001). In another derivation and validation cohort study, intra-aortic balloon pump use was a risk for CIN in patients undergoing coronary intervention (OR=5.1, p<0.0001) (Bartholomew et al., 2004).

2.3.2.3. Bypass graft intervention and delayed reperfusion

Procedures with bypass angiography and intervention may be associated with higher complexity, longer duration, and limited success, thus indicating an unstable post-procedural period with impaired cardiac output. Gruberg et al. showed that the risk of CIN requiring dialysis after PCI was increased with bypass graft intervention (OR=4.94) (Gruberg et al., 2001). In a study of 208 acute myocardial infarction patients undergoing primary PCI, the risk of CIN was increased if the time-to-reperfusion is ≥6 h (OR=2.51, p=0.04) (Marenzi et al., 2004)

2.3.3. Contrast medium-related risk factors

2.3.3.1. Increased dose of contrast medium

According to different sources, the relatively safe cutoff point of contrast amount varies from 70 ml up to 220ml. However, doses as low as 20 to 30 ml are capable of inducing CIN. In a study that patients undergoing coronary angiography, each 100 ml of contrast medium administered was associated with a significant increase of 12% in the risk of CIN (OR=1.12, p=0.02) (Rihal et al., 2002). Marenzi et al. showed that contrast volume >300 ml is an independent risk for CIN (OR=2.80, p=0.02) (Marenzi et al., 2004). In another study patients with preexisting renal failure revealed a 10-fold risk of CIN when more than 125 ml of contrast media was administered (Taliercio et al., 1986).

2.3.3.2. High-osmolar and ionic CM

Most side effects attributable to contrast medias are related to hypertonicity. Currently, four main types of contrast media are used in routine practice today, including nonionic low-osmolar, ionic low-osmolar, nonionic iso-osmolar, and ionic high-osmolar contrast media. In a large study which comparing the non-ionic low-osmolality agent iohexol to the ionic high-osmolality agent meglumine/sodium diatrizoate in patients with pre-existing renal dysfunction undergoing angiography, patients with renal insufficiency receiving diatrizoate were 3.3 times as likely to develop CIN compared to those receiving iohexol (Rudnick et al., 1995). NEPHRIC trial is a randomized, prospective study comparing the nonionic iso-osmolar CM iodixanol with the nonionic low-osmolar CM iohexol in 129 renal impairment patients with diabetes undergoing coronary or aorto-femoral
angiography. The incidence of CIN was 3% in the iodixanol group and 26% in the iohexol group ($p=0.002$) (Aspelin et al., 2003). In another randomized study, the renal tolerance of iodixanol and iohexol was compared in 124 patients with creatinine >1.7 mg/dl. The incidence of CIN was 3.7% in iodixanol group and 10% in iohexol group ($p>0.05$) (Chalmers et al., 1999). The available data do not provide clear evidence that the whole iso-osmolar CM class offers an improvement over the low-osmolar CM class. Other studies with iodixanol in renal failure patients have shown a higher incidence of CIN than that observed in the NEPHRIC study (21% in the RAPPID trial, 30% in the CONTRAST trial) (Baker et al., 2003; Stone et al., 2003). In addition to their osmolarity, contrast medias are characterized as ionic versus non-ionic. Small clinical trials of low-risk patients undergoing coronary angiography have shown little difference in the risk of CIN between the 2 types of CM. However, a randomized trial of 1196 patients undergoing coronary angiography showed that non-ionic CM reduced the incidence of CIN in patients with preexisting renal disease with or without diabetes (Rudnick et al., 1995). In addition, symptomatic or hemodynamic adverse drug events have been shown to occur less often with non-ionic, low-osmolality CM compared with ionic, high-osmolality CM. In high-risk patients, it is reasonable to don’t use the high-osmolar and ionic CM to minimize the risk of CIN.

2.3.3.3. Intra-arterial administration of the contrast media

Intra-arterial contrast administration is a risk for CIN. This effect is thought to be due to the fact that the acute intra renal concentration of CM is much higher after intra arterial rather than intravenous injection.

2.3.4. Scoring method to predict high risk patients for CIN

Mehran et al. developed a simple scoring method that integrates eight baseline clinical variables to assess the risk of CIN after percutaneous coronary intervention (PCI). These are hypotension (score 5), use of intra-aortic balloon pump (score 5), congestive heart failure (score 5), serum creatinine>1.5 mg/dl (score 4), age>75 years (score 4), anemia (score 3), diabetes mellitus (score 3), and volume of CM (score 1 per 100 ml). If the total score is 5 or less, the risk category is low; if the total score is 16 or higher, the risk category is very high (Mehran et al., 2004).

2.4. Prevention Strategies for CIN

Extracellular volume expansion with intravenous saline or sodium bicarbonate, minimizing the dose of CM, using low-osmolar non-ionic CM instead of high osmolar ionic CM, stopping the intake of nephrotoxic drugs and avoiding short intervals between procedures requiring CM have all been shown to be effective in reducing CIN. Alternatives to ordinary CM, such as carbon dioxide or gadolinium chelates, can be used in patients at high risk of CIN (Table 2).
Clinical evidence advocating their use  Don’t use  With conflicting or limited evidence

| Extracellular volume expansion | Nonsteroidal anti-inflammatory drugs, COX-2 inhibitors, aminoglycoside, cisplatin | Acetylcystein |
|--------------------------------|---------------------------------------------------------------------------------|--------------|
| Saline or sodium bicarbonate | Loop diuretics | Theophylline |
| Low or iso-osmolar contrast | Mannitol | Calcium channel blockers |
| Minimizing the dose of contrast | Multiple use of contrast within 72 h | Fenoldopam |
| Alternative imaging techniques | Large doses of contrast | Captopril |
| Monitoring serum creatinine | High-osmolar contrast | Ascorbic acid |
| Delaying contrast procedures until hemodynamic status is corrected | Metformin usage especially in patients with renal failure | Atrial natriuretic peptide |
| ≥48 h between contrast procedures | Endothelin antagonist | |
| | PGE1 | |
| | Hemofiltration | |
| | Nebivolol | |
| | Statins | |
| | B-type natriuretic peptide | |
| | Pentoxifylline | |

Table 2. Prevention strategies for contrast-induced nephropathy in high-risk patients

2.4.1. Volume expansion

Volume expansion is the single most important measure that has been documented to be beneficial in preventing CIN. A standardized saline hydration protocol has been proven effective in reducing the risk of CIN and should be used routinely. The most widely accepted protocol is administering isotonic saline at 1 to 1.5 ml/kg/h beginning 6 to 12 hours prior to the procedure and continuing for up to 12 hours following contrast administration. In a randomized trial, two different hydration regimens were compared in 1620 patients undergoing coronary interventions. They showed that the incidence of CIN was significantly lower among patients given an isotonic saline solution than among those given a hypotonic saline solution (0.7% vs. 2.0% respectively, p=0.04) (Mueller et al., 2002). In another trial, a total of 119 patients with serum creatinine exceeding 1.1 mg/dl were randomized to receive isotonic solution of sodium bicarbonate (n=59) or isotonic saline (n=60) at a rate of 3 ml/kg/h for 1 hour before and 1 ml/kg/h for 6 hours after contrast administration. CIN developed in only 1 patient (1.7%) compared with 8 patients (13.6%) in the saline group (p=0.02) (Merten et al., 2004). The authors postulated that a reduction in oxidative injury may have conferred protection against CIN. However, further studies are required to clarify the role of hydration with sodium bicarbonate in preventing CIN. In a prospective study, the effect of combi-
nation intravenous and oral volume supplementation on the development of CIN was studied in 425 patients undergoing percutaneous coronary intervention. Patients were randomly assigned to receive hydration with either isotonic or half-isotonic. In addition patients were encouraged to drink plenty of fluids (at least 1500 ml). They found that applying the combination of intravenous and oral volume supplementation results in a very low incidence of CIN (1.4%) (Mueller et al., 2005). Most studies have found that hydration alone is better than hydration combined with a diuretic. In a study, 78 patients with serum creatinine >1.6 mg/dl were randomized to three groups: hydration alone, hydration with mannitol and hydration with furosemide. Half-isotonic saline was used for hydration. CIN occurred in 11%, 28% and 40% of patients in the three groups, respectively (p=0.02), thus showing that forced diuresis is of no benefit in preventing CIN. In a meta-analysis it was found that the administration of sodium bicarbonate is superior to the administration of saline alone in the prevention of CIN (Solomon et al., 1994). The effectiveness of sodium bicarbonate treatment to prevent CIN in high-risk patients remains uncertain.

2.4.2. N-acetylcysteine

Antioxidant N-acetylcysteine (NAC) might scavenge oxygen free radicals, thus attenuate the cytotoxic effects of CM. NAC may also have direct vasodilating effects on the kidneys through an increase in the biologic effects of nitric oxide. Tepel et al. were evaluated the effects of NAC (600 mg orally twice daily), at first time, in 83 patients undergoing computed tomography. Two percent of the patients in the NAC group had CIN versus 21% in the placebo group (p=0.01) (Tepel et al., 2000). Since then, a number of trials have been published. Results from these trials have been inconsistent. In a randomized, placebo-controlled study it was found that NAC is protective against CIN Fifty-four patients were randomized to receive either 600 mg of NAC twice daily for 4 doses or placebo. The incidence of CIN was 8% in the NAC group versus 45% in the placebo group (p=0.005) (Diaz-Sandoval et al., 2002). In addition to oral administration, intravenous administration of NAC to protect against CIN has also been evaluated. In a study, Baker et al. randomly assigned 80 patients to receive either NAC infusion (n=41) versus saline infusion (n=39). CIN developed in only 2 (5%) of patients in the NAC group compared with 8 (21%) in the saline group (p=0.04) (Baker et al., 2003). The authors concluded that NAC infusion protects against CIN. In a meta-analysis, evaluating more than 800 patients at high risk of developing CIN also documented a positive impact of NAC prophylaxis on CIN (Birck et al., 2003). In another meta-analysis, nine randomized controlled trials were included and the difference in mean change in creatinine between the NAC treated group and controls was 0.27 mg/dl. The relative risk of developing CIN was 0.43 in subjects randomized to NAC. They suggest that NAC helps prevent declining renal function and CIN (Liu et al., 2005). In contrast to these reports, some studies failed to find a significant effect of NAC on the occurrence of CINA total of 183 patients with preexisting renal insufficiency undergoing contrast study were randomly assigned to receive NAC at a dose of 600 mg twice daily on the day before and the day of the contrast study plus saline infusion or saline alone. The incidence of CIN was 6.5% in the NAC group versus 11% in the control group (p=0.22) (Briguori et al., 2002). In a multi centric double blind
clinical trial 156 patients undergoing coronary angiography or percutaneous coronary intervention with creatinine clearance <50 ml/min were randomly assigned to receive N-acetylcysteine 600 mg orally twice daily for two days or placebo. Sixteen patients developed CIN. Eight of 77 patients (10.4%) in the NAC group and eight of 79 patients (10.1%) in the placebo group (p=1.00). No difference was observed in the change in endogenous creatinine clearance, p=0.28). They concluded that oral NAC did not prevent CIN in patients at low to moderate risk undergoing cardiac catheterisation with ionic low osmolality CM (Gomes et al., 2005). In another study, 50 patients undergoing elective diagnostic coronary angiography with serum creatinine values above 1.3 mg/dl were included and CIN was detected in 3 of 25 patients (12%) in the NAC group and 2 of 25 patients (8%) in the control group (p>0.05). It was detected that in patients planned to undergo elective diagnostic coronary angiography with renal dysfunction, oral NAC and hydration before the procedure was not more effective than hydration alone in the prevention of CIN (Gulel et al., 2005). A direct renoprotective effect of NAC remains questionable. To date, only a few trials described the effects of NAC not only on serum creatinine but also on clinical end points. The serum creatinine can be decrease in administration of NAC without renoprotective effect. In a prospective study, NAC was given at a dose of 600 mg every 12 h for a total of four doses to the volunteers with a normal renal function who did not receive contrast agent. There was a significant decrease of the mean serum creatinine (p<0.05) and a significant increase of the GFR (p<0.02), whereas the cystatin C concentration did not change significantly (Hoffmann et al., 2004). In patients undergoing emergency diagnostic procedures, in which a full hydration protocol is not possible, an abbreviated hydration regimen plus oral or intravenous administration of NAC can be recommended. NAC may be of benefit mostly in high-risk patients. If NAC is to be used as a preventative measure, it should be given at a dose of 600 mg orally twice daily on the day before and day of the procedure.

2.4.3. Ascorbic acid

Prophylactic oral administration of ascorbic acid may protect against CIN. In a randomized, placebo-controlled trial in 231 patients with serum creatinine ≥1.2 mg/dl who undergoing coronary angiography showed that the use of ascorbic acid was associated with a significant reduction in the rate of CIN. CIN occurred in 11 of the 118 patients (9%) in the ascorbic acid group and in 23 of the 113 patients (20%) in the placebo group (OR=0.38; p=0.02) (Spargias et al., 2004). Further prospective studies are needed to validate these preliminary results.

2.4.4. Fenoldopam

Fenoldopam mesylate is a selective dopamine-1 receptor agonist that produces systemic, peripheral and renal arterial vasodilatation. Several investigators have reported a positive impact of fenoldopam against CIN in small studies. In a placebo-controlled, double-blind, multicenter trial, 315 patients with creatinine clearance of less than 60 ml/min were randomized to receive fenoldopam infusion [0.05 µg/kg/min titrated to 0.1 µg/kg/min (n=157)] or matching placebo (n=158). CIN occurred in 33.6% of patients in the fenoldo-
pam group compared with 30.1% of patients in the placebo group (p=0.61) (Stone et al., 2003). The authors concluded that fenoldopam did not protect against CIN. In 2 other large studies comparing fenoldopam with NAC treatment with fenoldopam either had a similar, non significant effect as that of NAC or was inferior to it (Allaqaband et al., 2002; Briguori et al., 2004). The routine use of fenoldopam cannot be recommended at the present time.

2.4.5. Adenosine antagonists

CM stimulate the intrarenal secretion of adenosine, which binds to the renal adenosine receptor and acts as a potent vasoconstrictor, reducing renal blood flow and increasing the generation of oxygen free radicals as it is metabolized to xanthine and hypoxanthine. Theophylline and aminophylline, adenosine antagonists, have also been studied in the prevention of CIN in a number of trials. Studies with these agents have used varying doses and dosage forms and yielded conflicting results (Erley et al., 1999; Kapoor et al., 2001). Based on the conflicting information found in clinical studies, adenosine antagonists should not be routinely used in patients as a preventative measure at this time.

2.4.6. Calcium channel blockers

The calcium channel antagonists verapamil and diltiazem have been found to attenuate the renal vasoconstrictor response after exposure to CM. However, when the efficacy of the felodipine, nitrendipine and nifedipine was evaluated, results were inconsistent. Two small studies performed the use of sublingual nifedipine given prior to contrast administration. Patients (n=20) who received sublingual nifedipine did not have a significant increase in serum creatinine, while those in the placebo group did (Rodicio et al., 1990). In another study, patients (n=30) who received nifedipine had an increase in renal plasma flow following administration of contrast, while patients in the placebo group had a decrease in renal flow (Russo et al., 1990). One other study showed that nitrendipine use cause a significant reduction in the GFR in the placebo group compared to little or no change in GFR in the nitrendipine group (Neumayer et al., 1989). In another study, 27 patients with normal to moderately reduced renal function underwent femoral angiography randomized to receive either oral felodipine or placebo. Patients in the felodipine group had a significant increase in serum creatinine from baseline, while patients in the placebo group did not demonstrate a similar increase (Spangberg-Viklund et al., 1996). More large-scale trials are needed before calcium channel blockers can be routinely recommended in patients prior to CM administration.

2.4.7. Prostaglandin E$_1$

PGE$_1$ has vasodilatory effects that may be beneficial in preventing CIN. In one study, 130 patients were randomly assigned to receive either placebo or one of three doses of PGE$_1$. The increase in serum creatinine level was smaller in all of the three PGE$_1$ groups than in the placebo group, but the difference was significant only in the medium-dose (20 ng/kg/min) of
PGE\(_1\) group (Koch et al., 2000). More studies need to be done to better understand the role of prostaglandin E1, but results from this pilot study appear promising.

2.4.8. Atrial Natriuretic Peptide (ANP)

ANP may prevent CIN by increasing renal blood flow. In a study, ANP was included in one of the four arms. In which dopamine, mannitol, and ANP caused an increase in CIN in diabetic patients as compared to saline alone (Weisberg et al., 1994). In another trial patients were randomized to one of four treatment arms: fluid alone or one of three doses of ANP. Results showed no statistically significant differences in the incidence of CIN between any of the four treatment arms (Kurnik et al., 1998). Based on these results and the limited clinical data, ANP cannot be advocated in the prevention of CIN.

2.4.9. Endothelin antagonists

Endothelin-1 is a potent endogenous vasoconstrictor, is thought to play a role in the development of CIN. Endothelin-1 has two primary receptors. In animal studies, endothelin-A antagonists were shown to reduce the incidence of CIN (Liss et al., 2003). However, in a randomized study of 158 patients, the use of a mixed endothelin-A and B antagonist was associated with a significantly higher incidence of CIN than was placebo (56% vs. 29%, \(p=0.002\)) (Wang et al., 2000). Endothelin antagonists currently have no role in prevention of CIN.

2.4.10. Low-dose of dopamine

At low doses (1-3 mcg/kg/min), dopamine activates two types of dopamine (DA) receptors, DA-1 and DA-2. Activation of the DA-1 receptor results in an increase in natriuresis and renal blood flow. Since dopamine, at low doses, is believed to be more selective for the DA-1 receptors, it has been investigated in the prevention of CIN. Kapoor et al. randomized 40 patients with diabetes scheduled to undergo a coronary angiography to either dopamine or placebo control. None of the patients in the dopamine group developed CIN compared to 50% of patients receiving placebo (Kapoor et al., 2002). In another prospective, randomized trial, Hans et al. evaluated 55 patients (40% had diabetes) with chronic renal insufficiency. Patients were randomized to receive dopamine or an equal volume of saline. The group receiving dopamine had a significantly lower incidence of CIN as compared to the control group (Hans et al., 1998). In contrast to the trials showing a potential benefit of dopamine, other studies have failed to demonstrate this benefit. Abizaid et al. performed a randomized, prospective study involving patients with renal insufficiency who underwent coronary angioplasty. Patients were randomized to continue with the saline, receive aminophylline in addition to the saline, or receive dopamine plus saline. In the dopamine plus saline group, 50% of patients developed CIN, while only 30% of the patients in the saline-alone group developed CIN. This difference did not reach statistical significance, but it appeared that use of dopamine might worsen outcomes (Abizaid et al., 1999). Low-dose dopamine use cannot be supported at this time.
2.4.11. Statins

Whether additional benefits can be achieved with the use of statin in decreasing the risk of CIN remains undetermined. In a recent meta analysis of randomised controlled trials comparing statin pretreatment with non-statin pretreatment for the prevention of CIN, it was found that, the incidence of CIN was not significantly lower in statin pretreatment group as compared with control group (RR=0.76, p=0.30) (Zhang et al., 2011). The current cumulative evidence suggests that statin pretreatment may neither prevent CIN nor reduce the need for renal replacement therapy.

2.4.12. Nebivolol

In an experimental study we demonstrated that nebivolol have a protective role against CIN. Nebivolol leads to a decrease in the systemic and renal oxidative stress (p=0.001) and an increase in renal nitrite production (p=0.027). In addition, contrast-induced proteinuria, proteinaceous cast (p<0.001), and tubular necrosis (p=0.001) are restored by nebivolol (Toprak et al., 2008). Two recent human studies demonstrated the protective effect of nebivolol on CIN. One of the study showed that the use of oral nebivolol for one week at a dose of 5 mg per day decrease the incidence of CIN in patients who underwent coronary angiography with renal dysfunction (p=0.03) (Avci et al., 2011). Another more recent study showed that the use of oral nebivolol for 4 days at a dose of 5 mg per day is protective against nephrotoxic effects of CM in patients who underwent coronary angiography or ventriculography (Gunebakmaz et al., 2012). More large-scale trials are needed before nebivolol can be routinely recommended in prevention of CIN.

2.4.13. Hemofiltration and hemodialysis

Currently available data do not support use of prophylactic hemodialysis for prevention of CIN. In a trial of 113 patients, reported that CIN occurred in 24% of the hemodialysis group as compared with 16% of non-hemodialysis group (Vogt et al., 2001). Clinically relevant events also were not different in two groups. Only continuous venovenous hemofiltration has been shown to protect against CIN. In a study, 114 patients with chronic renal failure undergoing percutaneous coronary intervention were divided in two groups: 56 patients received normal saline and 58 patients underwent hemofiltration at a rate of 1000 ml/h (Marenzi et al., 2003). Hemofiltration seems to have a protective effect, including significant reduction in in-hospital and 1-year mortality compared with routine hydration. The mechanisms of this benefit are not clear. Further studies are needed to confirm the results of this trial.

2.4.14. New types of contrast media

Gadolinium-enhanced magnetic resonance coronary angiography is a non-invasive method for evaluation of coronary arteries. It has been suggested that gadolinium-based CM could be used in stead of iodinated CM for radiological examinations in patients with significant renal impairment. However, its use has been questioned on the basis of reports of nephro-
toxicity and its association with nephrogenic systemic fibrosis, a rare and serious syndrome that involves fibrosis of skin, joints, eyes, and internal organs. In a study by Hoffmann et al. the effect of gadopentetate dimeglumine (iodine-based CM) was studied in 181 patients with normal renal function and the effect of gadolinium was studied in 198 patients with pre-existing renal failure. There was no statistically significant change in serum creatinine concentration after gadopentetate dimeglumine. In contrary, serum creatinine levels decreased significantly after the administration of gadolinium (p<0.01) (Hoffmann et al., 2005). In a retrospective study, the safety of gadolinium was evaluated in 91 patients with stage 3 and 4 renal failure who underwent angiographic MRI procedures. Eleven of 91 patients developed CIN (12.1%) (Ergun et al., 2006). In another randomized study gadobutrol, a gadolinium-based CM, was compared with standard iohexol, an iodinated CM, in 21 patients with renal dysfunction. The incidence of CIN was 50% in gadobutrol group and 45% in iohexol group (p=0.70). In this study, gadolinium showed no benefit over iohexol in patients with severely impaired renal function (Erley et al., 2004). More studies need to be done to better understand the role of gadolinium on CIN. Ultrasound contrast agents are micro-bubbles which produce acoustic enhancement. They are pharmacologically almost inert and safe.

3. Conclusion

The development of CIN is associated with adverse outcomes including prolonged hospitalization, the potential need for renal replacement therapy, and most important, increased mortality. The treatment of established CIN is limited to supportive measures and dialysis. For this reason, screening for high-risk patients before CM including -cardiac procedures and taking the appropriate prophylactic regimens is important in reducing CIN. Pre-existing renal dysfunction, especially when secondary to diabetic nephropathy, is the most important risk factor. Extra cellular volume expansion and use of low osmolar CM are the two most effective measures to prevent CIN. Acetylcysteine may use in high-risk patients, and nebivolol may use as a new prophylactic agent for CIN, but this finding has not been uniform or always demonstrated by currently available trials.

Author details

Omer Toprak

Department of Medicine, Division of Nephrology, Balikesir University School of Medicine, Balikesir, Turkey

References

[1] Abizaid, AS., Clark, CE., Mintz, GS., Dosa, S., Popma, JJ., Pichard, AD., Satler, LF., Harvey, M., Kent, KM., & Leon, MB. (1999). Effects of Dopamine and Aminophylline
on Contrast-Induced Acute Renal Failure after Coronary Angioplasty in Patients with Preexisting Renal Insufficiency. *The American Journal of Cardiology*, Vol.83, No.2, (January 1999), pp.260-263, ISSN 0002-9149

[2] Ahuja, TS., Niaz, N., & Agraharkar, M. (2000). Contrast-Induced Nephrotoxicity in Renal Allograft Recipients. *Clinical Nephrology*, Vol.54, No.1, (July 2000), pp.11-14, ISSN 0301-0430

[3] Allaqaband, S., Tumuluri, R., Malik, AM., Gupta, A., Volkert, P., Shalev, Y., & Bajwa, TK. (2002). Prospective Randomized Study of N-Acetylcysteine, Fenoldopam, and Saline for Prevention of Radiocontrast-Induced Nephropathy. *Catheterization and Cardiovascular Interventions*, Vol.57, No.3, (November 2002), pp.279-283, ISSN 1522-1946

[4] Aspelin, P., Aubry, P., Fransson, SG., Strasser, R., Willenbrock, R., & Berg, KJ. (2003). Nephrotoxic Effects in High-Risk Patients Undergoing Angiography. *The New England Journal of Medicine*, Vol.348, No.6, (February 2003), pp.491-499, ISSN 0028-4793

[5] Avci, E., Yeşil, M., Bayata, S., Postaci, N., Arikan, E., & Cirit, M. (2011). The Role of Nebivolol in The Prevention of Contrast-Induced Nephropathy in Patients with Renal Dysfunction. *The Anatolian Journal of Cardiology*, Vol.11, No.7, (November 2011), pp.613-617, ISSN 1302-8723

[6] Baker, CS., Wragg, A., Kumar, S., De Palma, R., Baker, LR., & Knight, CJ. (2003). A Rapid Protocol for the Prevention of Contrast-Inducted Renal Dysfunction: The RAP-PID Study. *Journal of the American College of the Cardiology*, Vol. 41, No. 12, (June 2003), pp.2114-2118, ISSN 0735-1097

[7] Bartholomew, BA., Harjai, KJ., Dukkipati, S., Boura, JA., Yerkey, MW., Glazier, S., Grines, CL., & O'Neill, WW. (2004). Impact of Nephropathy after Percutaneous Coronary Intervention and a Method for Risk Stratification, *The American Journal of Cardiology*, Vol.93, No.12, (June 2004), pp.1515-1519, ISSN 0002-9149

[8] Barrett, BJ., Parfrey, PS., Vavasour HM., McDonald, J., Kent, G., Hefferton, D., O'Dea, F., Stone, E., Reddy, R., & McManamon, PJ. (1992). Contrast Nephropathy in Patients with Impaired Renal Function: High Versus Low Osmolar Media. *Kidney International*, Vol.41, No.5, (May 1992), pp. 1274–1279, ISSN 0085-2538

[9] Birck, R., Krzossok, S., Markowetz, F., Schnulle, P., van der Woude, FJ., & Braun, C. (2003). Acetylcysteine for Prevention of Contrast Nephropathy: Meta-Analysis. *Lancet*, Vol.362, No.9384, (August 2003), pp.598-603, ISSN 0140-6736

[10] Briguori, C., Manganelli, F., Scarpato, P., Elia, PP., Golia, B., Riviezzo, G., Lepore, S., Librera, M., Villari, B., Colombo, A., & Ricciardelli, B. (2002). Acetylcysteine and Contrast Agent-Associated Nephrotoxicity. *Journal of the American College of the Cardiology*, Vol.40, No.2, (July 2002), pp. 298-303, ISSN 0735-1097

[11] Briguori, C., Colombo, A., Airoldi, F., Violante, A., Castelli, A., Balestrieri, P., Paolo Elia, P., Golia, B., Lepore, S., Riviezzo, G., Scarpato, P., Librera, M., Focaccio, A., & Ricciardelli, B. (2004). N-Acetylcysteine Versus Fenoldopam Mesylate to Prevent
Contrast Agent-Associated Nephrotoxicity. *Journal of the American College of the Cardiology*, Vol.44, No.4, (August 2004), pp.762-765, ISSN 0735-1097

[12] Chalmers, N., & Jackson, RW. (1999). Comparison of Iodixanol and Iohexol in Renal Impairment. *The British Journal of Radiology*, Vol.72, No.859, (July 1999), pp.701-703, ISSN 0007-1285

[13] Cirit, M., Toprak, O., Yesil, M., Bayata, S., Postaci, N., Pupim, L., & Esi, E. (2006). Angiotensin-Converting Enzyme Inhibitors as a Risk Factor for Contrast-Induced Nephropathy. *Nephron Clinical Practice*, Vol.104, No.1, (August 2006), pp. c20-c27, ISSN 1660-2110

[14] Dangas, G., Iakovou, I., Nikolsky, E., Aymong, ED., Mintz, GS., Kipshidze, NN., Lansky, AJ., Moussa, I., Stone, GW., Moses, JW., Leon, MB., & Mehran, R. (2005). Contrast-Induced Nephropathy After Percutaneous Coronary Interventions in Relation to Chronic Kidney Disease and Hemodynamic Variables. *The American Journal of Cardiology*, Vol.95, No.1, (January 2005), pp. 13-19, ISSN 0002-9149

[15] Diaz-Sandoval, LJ., Kosowsky, BD., & Losordo, DW. (2002). Acetylcysteine to Prevent Angiography-Related Renal Tissue Injury (The APART Trial). *American Journal of Cardiology*, Vol.89, No.3, (February 2002), pp.356-358, ISSN 0002-9149

[16] Ergun, I., Keven, K., Uruç, I., Ekmekci, Y., Canbakan, B., Erden, I., & Karatan, O. (2006). The Safety of Gadolinium in Patients with Stage 3 and 4 Renal Failure. *Nephrology Dialysis Transplantation*, Vol.21, No.3, (March 2006), pp. 697-700, ISSN 0931-0509

[17] Erley, CM., Bader, BD., Berger, ED., Tuncel, N., Winkler, S., Tepe, G., Risler, T., & Duda, S. Gadolinium-Based Contrast Media Compared with Iodinated Media for Digital Subtraction Angiography in Azotaemic Patients. *Nephrology Dialysis Transplantation*, Vol.19, No.10, (October 2004), pp.2526-2531, ISSN 0931-0509

[18] Erley, CM., Duda, SH., Rehfuss, D., Scholtes, B., Bock, J., Muller, C., Osswald, H., & Risler, T. (1999). Prevention of Radiocontrast Media-Induced Nephropathy in Patients with Pre-Existing Renal Insufficiency by Hydration in Combination with the Adenosine Antagonist Theophylline. *Nephrology Dialysis Transplantation*, Vol.14, No.5, (May 1999), pp.1146–1149, ISSN 0931-0509

[19] Gomes, VO., Poli de Figueredo, CE., Caramori, P., Lasevitch, R., Bodanese, LC., Araujo, A., Roedel, AP., Caramori, AP., Brito, FS Jr., Bezerra, HG., Nery, P., & Brizolara, A. (2005). N-Acetylcysteine Does Not Prevent Contrast Induced Nephropathy after Cardiac Catheterisation with an Ionic Low Osmolality Contrast Medium: A Multicentre Clinical Trial. *Heart*, Vol.91, No.6, (June 2005), pp.774-778, ISSN 1355-6037

[20] Gruberg, L., Mehran, R., Dangas, G., Mintz, GS., Waksman, R., Kent, KM., Pichard, AD., Satler, LF., Wu, H., & Leon, MB. (2001). Acute Renal Failure Requiring Dialysis after Percutaneous Coronary Interventions. *Catheterization and Cardiovascular Interventions*, Vol.52, No.4, (April 2001), pp.409-416, ISSN 1522-1946
[21] Gulel, O., Keles, T., Eraslan, H., Aydogdu, S., Diker, E., & Ulusoy, V. (2005). Prophylactic Acetylcysteine Usage for Prevention of Contrast Nephropathy after Coronary Angiography. *Journal of Cardiovascular Pharmacology, Vol.46, No.4, (October 2005)*, pp. 464-467, ISSN 0160-2446

[22] Gunebakmaz, O., Kaya, MG., Koc, F., Akpek, M., Kasapkara, A., Inanc, MT., Yarlioglues, M., Calapkorur, B., Karadag, Z., & Oguzhan, A. (2012). Does nebivolol prevent contrast-induced nephropathy in humans? Clinical Cardiology, *Vol.35, No.4, (April 2012)*, pp.250-254, ISSN 1932-8737

[23] Gupta, RK., Kapoor, A., Tewari, S., Sinha, N., & Sharma, RK. (1999). Captopril for Preventing of Contrast-Induced Nephropathy in Diabetic Patients: A Randomized Study. *Indian Heart Journal, Vol.51, No.5, (September 1999)*, pp.521–526, ISSN 0019-4832

[24] Hans, SS., Hans, BA., Dhillon, R., Dmuchowski, C., & Glover, J. (1998). Effect of Dopamine on Renal Function after Arteriography in Patients With Preexisting Renal Insufficiency. *The American Surgeon, Vol.34, No.5, (May 1998)*, pp.1682-1688, ISSN 0003-1348

[25] Hoffmann, U., Fischereder, M., Reil, A., Fischer, M., Link, J., & Kramer, BK. (2005). Renal Effects of Gadopentetate Dimeglumine in Patients with Normal and Impaired Renal Function. *European Journal of Medical Research, Vol. 10, No.4, (April 2005)*, pp. 149-154, ISSN 0949-2321

[26] Hoffmann, U., Fischereder, M., Kruger, B., Drobnik, W.; & Kramer, BK. (2004). The Value of N-Acetylcysteine in the Prevention of Radiocontrast Agent-Induced Nephropathy Seems Questionable. *Journal of the American Society of Nephrology, Vol.15, No.2, (February 2004)*, pp.407–410, ISSN 1046-6673

[27] Holland, MD., Galla, JH., Sanders, PW., & Luke, RG. (1985). Effect of Urinary pH and Diatrizoate on Bence Jones Protein Nephrotoxicity in the Rat. *Kidney International, Vol.27, No.1, (January 1985)*, pp. 46-50, ISSN 0085-2538

[28] Iakovou, I., Dangas, G., Mehran, R., Lansky, AJ., Ashby, DT., Fahy, M., Mintz, GS., Kent, KM., Pichard, AD., Satler, LF., Stone, GW., & Leon, MB. (2003). Impact of Gender on the Incidence and Outcome of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention. *The Journal of Invasive Cardiology, Vol.15, No.1, (January 2003)*, pp. 18–22, ISSN 1042-3931

[29] Kapoor, A., Kumar, S., Gulati, S., Gambhir, S., Sethi, RS., & Sinha, N. The Role of Theophylline in Contrast-Induced Nephropathy: A Case-Control Study. *Nephrology Dialysis Transplantation*, *Vol. 17, No.11, (November 2002)*, pp.1936–1941, ISSN 0931-0509

[30] Kapoor, A., Sinha, N., Sharma, RK., Shrivastava, S., Radhakrishnan, S., Goel, PK., & Bajaj R. (1996). Use of Dopamine in Prevention of Contrast Induced Acute Renal Failure: A Randomized Study. *International Journal of Cardiology, Vol.53, No.3, (March 1996)*, pp.233-236, ISSN 0167-5273
[31] Kiski, D., Stepper, W., Brand, E., Breithardt, G., & Reinecke, H. (2010). Impact of Renin-Angiotensin-Aldosterone Blockade by Angiotensin-Converting Enzyme Inhibitors or AT-1 Blockers on Frequency of Contrast Medium-Induced Nephropathy: A Post-Hoc Analysis from the Dialysis-Versus-Diuresis (DVD) Trial. *Nephrology Dialysis Transplantation*, Vol.25, No.3, (May 2010), pp.759-64, ISSN 0931-0509

[32] Koch, JA., Plum, J., Grabensee, B., & Modder, U. (2000). Prostaglandin E1: A New Agent for the Prevention of Renal Dysfunction in High Risk Patients Caused by Radiocoustic Media? *Nephrology Dialysis Transplantation*, Vol. 15, No.1, (January 2000), pp.43-49, ISSN 0931-0509

[33] Kohli, HS., Bhaskaran, MC., Muthukumar, T., Thennarasu, K., Sud, K., Jha, V., Gupta, KL., & Sakhuja, V. (2000). Treatment-Related Acute Renal Failure in the Elderly: A Hospital-Based Prospective Study. *Nephrology Dialysis Transplantation*, Vol.15, No.2, (February 2000), pp. 212-217, ISSN 0931-0509

[34] Kurnik, BR., Allgren, RL., Genter, FC., Solomon, RJ., Bates, ER., & Weisberg, LS. (1998). Prospective Study of Atrial Natriuretic Peptide for the Prevention of Radiocontrast-Induced Nephropathy. *American Journal of the Kidney Diseases*, Vol.31, No.4, (April 1998), pp.674-680, ISSN 0272-6386

[35] Lautin, EM., Freeman, NJ., Schoenfeld, AH., Bakal, CW., Haramati, N., Friedman, AC., Lautin, JL., Braha, S., Kadish, EG., & Sprayregen, S. (1991). Radiocontrast-Associated Renal Dysfunction: Incidence and Risk Factors. *AJR American Journal of Roentgenology*, Vol.157, No.1, (July 1991), pp. 49–58, ISSN 0002-9243

[36] Liss, P., Carlsson, PO., Nygren, A., Palm, F., & Hansell, P. (2003). ET-A Receptor Antagonist BQ123 Prevents Radiocontrast Media-Induced Renal Medullary Hypoxia. *Acta Radiologica*, Vol.44, No.1, (January 2003), pp.111-117, ISSN 0284-1851

[37] Liu, R., Nair, D., Ix, J., Moore, DH., & Bent, S. (2005). N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy. A Systematic Review and Meta-Analysis. *Journal of General Internal Medicine*, Vol.20, No.2, (February 2005), pp.193-200, ISSN 0884-8734

[38] McCarthy, CS., & Becker, JA. (1992). Multiple Myeloma and Contrast Media. *Radiology*, Vol.183, No.2, (May 1992), pp.519–521, ISSN 0033-8419

[39] McCullough, PA., Wolyn, R., Rocher, LL., Levin, RN., & O’Neill, WW. (1997). Acute Renal Failure after Coronary Intervention: Incidence, Risk Factors, and Relationships to Mortality. *The American Journal of Medicine*, Vol.103, No.5, (November 1997), pp. 368–375, ISSN 0002-9243

[40] Marenzi, G., Lauri, G., Assanelli, E., Campodonico, J., De Metrio, M., Marana, I., Grazzi, M., Veglia, F., & Bartorelli, AL. (2004). Contrast-Induced Nephropathy in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. *Journal of the American College of the Cardiology*, Vol.44, No.9, (November 2004), pp. 1780-1785, ISSN 0735-1097
[41] Marenzi, G., Marana, I., Lauri, G., Assanelli, E., Grazi, M., Campodonico, J., Trabattoni, D., Fabbrocchi, F., Montorsi, P., & Bartorelli, AL. (2003). The Prevention of Radiocontrast-Agent-Induced Nephropathy by Hemofiltration. *The New England Journal of Medicine*, Vol.349, No.14, (October 2003), pp.1333-1340, ISSN 0028-4793

[42] Mehran, R., Aymong, ED., Nikolsky, E., Lasic, Z., Iakovou, I., Fahy, M., Mintz, GS., Lansky, AJ., Moses, JW., Stone, GW., Leon, MB., & Dangas, G. (2004). A Simple Risk Score for Prediction of Contrast-Induced Nephropathy after Percutaneous Coronary Intervention: Development and Initial Validation. *Journal of the American College of Cardiology*, Vol.44, No.7, (October 2004), pp.1393-1399, ISSN 0735-1097

[43] Merten, GJ., Burgess, WP., Gray, LV., Holleman, JH., Roush, TS., Kowalchuk, GJ., Bersin, RM., Van Moore, A., Simonton, CA 3rd., Rittase, RA., Norton, HJ., & Kennedy, TP. (2004). Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *Journal of the American Medical Association*, Vol.291, No.19, (May 2004), pp.2328-2334, ISSN 0098-7484

[44] Moore, RD., Steinberg, EP., Powe, NR., Brinker, JA., Fishman, EK., Graziano, S., & Gopalan, R. (1992). Nephrotoxicity of High-Osmolarity vs Low-Osmolarity Contrast Media: Randomized Clinical Trial. *Radiology*, Vol.182, No.3, (March 1992), pp. 649–655, ISSN 0033-8419

[45] Mueller, C., Seidensticker, P., Buettner, HJ., Perruchoud, AP., Staub, D., Christ, A., & Buerkle, G. (2005). Incidence of Contrast Nephropathy in Patients Receiving Comprehensive Intravenous and Oral Hydration. Swiss Medical Weekly, Vol.135, No.19, (May 2005), pp.286-290, ISSN 1424-7860

[46] Mueller, C., Buerkle, G., Buettner, HJ., Petersen, J., Perruchoud, AP., Eriksson, U., Marsch, S., & Roskamm, H. (2002). Prevention of Contrast Media-Associated Nephropathy: Randomized Comparison of 2 Hydration Regimens In 1620 Patients Undergoing Coronary Angioplasty. *Archives of Internal Medicine*, Vol.162, No.3, (February 2002), pp.329-336, ISSN 0003-9926

[47] Neumayer, HH., Junge, W., Kufner, A., & Wening, A. (1989). Prevention of Radiocontrast-Media-Induced Nephrotoxicity by the Calcium Channel Blocker Nitrendipine: A Prospective Randomized Clinical Trial. *Nephrology Dialysis Transplantation*, Vol.4, No.12, (April 1989), pp.1030-1036, ISSN 0931-0509

[48] Nikolsky, E., Mehran, R., Lasic, Z., Mintz, GS., Lansky, AJ., Na, Y., Pocock, S., Negoi-ta, M., Moussa, I., Stone, GW., Moses, JW., Leon, MB., & Dangas, G. Low Hematocrit Predicts Contrast-Induced Nephropathy After Percutaneous Coronary Interventions. *Kidney International*, Vol.67, No.2, (February 2005), pp.706-713, ISSN 0085-2538

[49] Parfrey, PS., Griffiths, SM., Barrett, BJ., Paul, MD., Genge, M., Withers, J, Farid, N., & McManamon, PJ. (1989). Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both. A Prospective Controlled Study. *The New England Journal of Medicine*, Vol.320, No.3, (January 1989), pp.143-149, ISSN 0028-4793
[50] Perrin, T., Descombes, E., & Cook S. (2012). Contrast-Induced Nephropathy in Invasive Cardiology. Swiss Medical Weekly, Vol.142, No.13608, (June 2012), ISSN1424-7860

[51] Rich, MW., & Crecelius, CA. (1990). Incidence, Risk Factors, and Clinical Course of Acute Renal Insufficiency after Cardiac Catheterization in Patients 70 Years of Age or Older. A Prospective Study. Archives of Internal Medicine, Vol.150, No.6, (June 1990), pp. 1237-1242, ISSN 0003-9926

[52] Rihal, CS., Textor, SC., Grill, DE., Berger, PB., Ting, HH., Best, PJ., Singh, M., Bell, MR., Barsness, GW., Mathew, V., Garratt, KN., & Holmes, DR Jr. (2002). Incidence and Prognostic Importance of Acute Renal Failure after Percutaneous Coronary Intervention. Circulation, Vol.105, No.105, (May 2002), pp. 2259-2264, ISSN 0009-7322

[53] Rodicio, JL., Morales, JM., & Ruilope, LM. (1990). Calcium Antagonists and the Kidney. Nephrology Dialysis Transplantation, Vol.5, No.2, (1990), pp.81-86, ISSN 0931-0509

[54] Rudnick, MR., Goldfarb, S., Wexler, L., Ludbrook, PA., Murphy, MJ., Halpern, EF., Hill, JA., Winniford, M., Cohen, MB., & Van Fossen, DB. (1995). Nephrotoxicity of Ionic and Nonionic Contrast Media in 1196 Patients: A Randomized Trial. The Iohexol Cooperative Study. Kidney International, Vol.47, No.1, (January 1995), pp. 254-261, ISSN 0085-2538

[55] Russo, D., Testa, A., Della Volpe, L., & Sansone, G. (1990). Randomised Prospective Study on Renal Effects of Two Different Contrast Media in Humans: Protective Role of a Calcium Channel Blocker. Nephron, Vo.55, No.3, (1990), pp.254-257, ISSN 0028-2766

[56] Sadeghi, HM., Stone, GW., Grines, CL., Mehran, R., Dixon, SR., Lansky, AJ., Fahy, M., Cox, DA., Garcia, E., Tcheng, JE., Griffin, JJ., Stuckey, TD., Turco, M., & Carroll, JD. (2003). Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. Circulation, Vol.108, No.22, (December 2003), pp. 2769-2775, ISSN 0009-7322

[57] Shaker, OG., El-Shehaby, A., & El-Khatib, M. (2010). Early Diagnostic Markers for Contrast Nephropathy in Patients Undergoing Coronary Angiography. Angiology, Vol.61, No.8, (November 2010), pp. 731-736, ISSN 0003-3197

[58] Solomon, R., Werner, C., Mann, D., D’Elia, J., & Silva, P. (1994). Effects of Saline, Mannitol and Furosemide to Prevent Acute Decreases in Renal Function Induced by Radiocontrast Agents. The New England Journal of Medicine, Vol. 331, No.21, (November 1994), pp.1416–1420, ISSN 0028-4793

[59] Spangberg-Viklund, B., Berglund, J., Nikonoff, T., Nyberg, P., Skau, T., & Larsson, R. (1996). Does Prophylactic Treatment with Felodipine, a Calcium Antagonist, Prevent Low-Osmolar Contrast Induced Renal Dysfunction in Hydrated Diabetic and Non-diabetic Patients with Normal or Moderately Reduced Renal Function? Scandinavian Journal of Urology and Nephrology, Vol.30, No.1, (February 1996), pp.63-68, ISSN 0036-5599
[60] Spargias, K., Alexopoulos, E., Kyrzopoulos, S., Iokvis, P., Greenwood, DC., Manginas, A., Voudris, V., Pavlides, G., Buller, CE., Kremastinos, D., & Kokkinos, DV. (2004). Ascorbic Acid Prevents Contrast-Mediated Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Angiography or Intervention. *Circulation*, Vol.110, No.18, (November 2004), pp.2837-2842, ISSN 0009-7322

[61] Stone, GW., McCullough, PA., Tumlin, JA., Lepor, NE., Madyoon, H., Murray, P., Wang, A., Chu, AA., Schaefer, GL., Stevens, M., Wilensky, RL., & O'Neill, WW., CONTRAST Investigators. (2003). Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy: A Randomized Controlled Trial. *The Journal of the American Medical Association*, Vol.290, No.17, (November 2003), pp.2284-2291, ISSN 0098-7484

[62] Taliercio, CP., Vlietstra, RE., Fisher, LD., & Burnett, JC. (1986). Risks for Renal Dysfunction with Cardiac Angiography. *Annals of Internal Medicine*, Vol.104, No.4, (April 1986), pp.501-504, ISSN 0003-4819

[63] Tepel, M., van Der Giet, M., Schwarzfeld, C., Laufer, U., Liermann, D., & Zidek, W. (2000). Prevention of Radiographic-Contrast-Agent-Induced Reductions in Renal Function by Acetylcysteine. *The New England Journal of Medicine*, Vol.343, No.3, (July 2000), pp.180-184, ISSN 0028-4793

[64] Toprak, O., Cirit, M., Tanrisev, M., Yazici, C., Canoz, O., Sipahioglu, M., Uzum, A., Ersoy, R., & Sozmen, EY. (2008). Preventive Effect of Nebivolol on Contrast-Induced Nephropathy in Rats. *Nephrology Dialysis Transplantation*, Vol.23, No.3, (March 2008), pp. 853-859, ISSN 0931-0509

[65] Toprak, O. (2007). Conflicting and New Risk Factors for Contrast-Induced Nephropathy. *The Journal of Urology*, Vol. 178, No.6, (December 2007), pp. 2277-2283, ISSN 0022-5347

[66] Toprak, O., Cirit, M., Yesil, M., Bayata, S., Tanrisev, M., Varol, U., Ersoy, R., & Esi, E. (2007). Impact of Diabetic and Pre-Diabetic State on Development of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease. *Nephrology Dialysis Transplantation*, Vol.22, No.3, (March 2007), pp. 819-826, ISSN 0931-0509

[67] Toprak, O., Cirit, M., Yesil, M., Byrne DW, Postaci, N., Bayata, S., Majchrzak, KM., & Esi, E. (2006). Metabolic Syndrome as a Risk Factor for Contrast-Induced Nephropathy in Non-Diabetic Elderly Patients with Renal Impairment. *Kidney and Blood Pressure Research*, Vol.29, No.1, (June 2006), pp. 2-9, ISSN 1420-4096

[68] Toprak, O., Cirit, M., Esi, E., Postaci, N., Yesil, M., & Bayata, S. (2007). Hyperuricemia as a Risk Factor for Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease. *Catheterization and Cardiovascular Interventions*, Vol.67, No.2, (February 2006), pp. 227-235, ISSN 1522-1946

[69] Toprak, O., & Cirit, M. (2006). Risk Factors and Therapy Strategies for Contrast-Induced Nephropathy. *Renal Failure*, Vol. 28, No. 5, (January 2006), pp. 365-381, ISSN 0886-022X
[70] Toprak, O., & Cirit, M. (2005). Investigating the Volume Status Before Contrast Nephropathy Studies. *Nephrology Dialysis Transplantation*, Vol.20, No.2, (February 2005), pp. 464, ISSN 0931-0509

[71] Toprak, O., Cirit, M., Bayata, S., Yesil, M., & Aslan, SL. (2003). The Effect of Pre-procedural Captopril on Contrast-Induced Nephropathy in Patients who Underwent Coronary Angiography. *Anadolu Kardiyoloji Dergisi*, Vol. 3, No.2, (June 2003), pp. 98-103, ISSN 1302-8723

[72] Toprak, O., Cirit, M., Bayata, S., Aslan, SL., Sarioglu, F., & Cetinkaya, GS. (2003). Is There Any Relationship Between Left Ventricular Ejection Fraction and Contrast Induced Nephropathy? *Türkiye Klinikleri Journal of Medical Sciences*, Vol 23, No. 2, (March 2003), pp. 104-107, ISSN 0002-9243

[73] Vogt, B., Ferrari, P., Schonholzer, C., Marti, HP., Mohaupt, M., Wiederkehr, M., Cereghetti, C., Serra, A., Huynh-Do, U., Uehlinger, D., & Frey, FJ. (2001). Prophylactic Hemodialysis after Radiocontrast Media in Patients with Renal Insufficiency is Potentially Harmful. *The American Journal of Medicine*, Vol.111, No.9, (December 2001), pp.692-698, ISSN 0002-9243

[74] Wang, A., Holcslaw, T., Bashore, TM., Freed, MI., Miller, D., Rudnick, MR., Szerlip, H., Thames, MD., Davidson, CJ., Shusterman, N., & Schwab, SJ. (2000). Exacerbation of Radiocontrast Nephrotoxicity by Endothelin Receptor Antagonism. *Kidney International*, Vol.57, No.4, (April 2000), pp.1675-1680, ISSN 0085-2538

[75] Weber-Mzell, D., Kotanko, P., Schumacher, M., Klein, W., & Skrabal, F. (2002). Coronary Anatomy Predicts Presence or Absence of Renal Artery Stenosis. A Prospective Study in Patients Undergoing Cardiac Catheterization for Suspected Coronary Artery Disease. *European Heart Journal*, Vol.23, No.21, (November 2002), pp.1684–1691, ISSN 0195-668x

[76] Weinrauch, LA., Healy, RW., Leland, OS Jr., Goldstein, HH., Kassissieh, SD., Libertino, JA., Takacs, FJ., & D’Elia, JA. (1977). Coronary Angiography and Acute Renal Failure in Diabetic Azotemic Nephropathy. *Annals of Internal Medicine*, Vol.86, No.1, (January 1977), pp.56-59, ISSN 0003-4819

[77] Weisberg, LS., Kurnik, PB., & Kurnik, BR. (1994). Risk of Radiocontrast Nephropathy in Patients with and without Diabetes Mellitus. *Kidney International*, Vol.45, No.1, (January 1994), pp.259-265,ISSN 0085-2538

[78] Yang, DW., Jia, RH., Yang, DP., Ding, GH., & Huang, CX. (2004). Dietary Hypercholesterolemia Aggravates Contrast Media-Induced Nephropathy. *Chinese Medical Journal*, Vol. 117, No.4 (April 2004), pp.542–546, ISSN 0366-6999.

[79] Zhang, L., Zhang, L., Lu, Y., Wu, B., Zhang, S., Jiang, H., Ge, J., & Chen, H. (2011). Efficacy of Statin Pretreatment for the Prevention of Contrast-Induced Nephropathy: A Meta-Analysis of Randomised Controlled Trials. *International Journal of Clinical Practice*, Vol.65, No.5, (May 2011), pp.624-30, ISSN 1368-5031